A Prospective Clinical Trial of Radiotherapy Combined with PD-1 Inhibitors and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Advanced Refractory Solid Tumors

被引：0
|
作者：
Xing, P. [1 ,2 ,3 ]
Yang, J., Sr. [1 ]
Xu, M. [1 ]
Kong, Y. [1 ]
Zhang, J. [1 ]
Zhao, X. [1 ]
Zhang, L. [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
[2] Soochow Univ, Inst Radiotherapy & Oncol, Suzhou, Peoples R China
[3] Suzhou Key Lab Radiat Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2336
引用
收藏
页码：E157 / E158
页数：2
相关论文
共 40 条
  • [31] Efficacy of Brentuximab-Vedotin Combined with PD-1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma with ASCT Consolidation and Maintenance Therapy: A Phase 2 Clinical Trial
    Chavez, Isaac Daniel Barrera
    alvarez, Juan Carlos Viloria
    Sanchez, Veronica Zendejas
    Esquivel, Amelie Rodriguez
    Salinas, Alejandra Alvarez
    Medina, Lauro Fabian Amador
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025,
  • [32] RESULTS OF A PHASE I TRIAL OF FT500, A FIRST-IN-CLASS, OFF-THE-SHELF, IPSC-DERIVED NK CELL THERAPY COMBINED WITH PD-1/PD-L1 CHECKPOINT BLOCKADE THERAPY AND IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Patel, Sandip
    Patel, Manish
    Gutierrez, Martin
    Anderson, Marlisa
    Szabo, Peter
    Valamehr, Bob
    Chu, Yu-Waye
    Beagle, Brandon
    Chou, Jeffrey
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A787 - A787
  • [33] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [34] Chemo-immunotherapy regimen with gemcitabine plus FOLFOX 4 (GOLF) followed by subcutaneous (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2). Results from a multicenter phase II trial in colon carcinoma patients.
    Correale, P.
    Remondo, C.
    Montagnani, F.
    Rotundo, M. S.
    Marsili, S.
    Laplaca, M.
    Tassone, P.
    Tagliaferri, P.
    Venuta, S.
    Francini, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 167S - 167S
  • [35] Forty-three week follow-up of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients
    Head, Jonathan F.
    Daniels, Gregory A.
    McKinney, Michelle
    Wang-Rodriguez, Jessica
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [36] HEMATOPOIETIC RECOVERY FOLLOWING HIGH-DOSE COMBINED ALKYLATING-AGENT CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT IN PATIENTS IN PHASE-I CLINICAL-TRIALS OF COLONY-STIMULATING FACTORS - G-CSF, GM-CSF, IL-1, IL-2, M-CSF
    LAUGHLIN, MJ
    KIRKPATRICK, G
    SABISTON, N
    PETERS, W
    KURTZBERG, J
    ANNALS OF HEMATOLOGY, 1993, 67 (06) : 267 - 276
  • [37] Serial assessment of GEN2, a retroviral vector for gene transfer of an optimized thymidine kinase and GM-CSF, for genomic integration into peripheral blood mononuclear cells (PBMCs) in a Phase 1 clinical trial in adult patients with solid tumors
    Hannah, Alison L.
    Kasahara, Noriyuki
    Liu, Li
    Wang, Allen
    McNulty, Joe
    Johnson, Robert G.
    CANCER RESEARCH, 2024, 84 (06)
  • [38] EMERGING SAFETY AND ACTIVITY DATA FROM GEN009-101: A PHASE 1/2A TRIAL OF GEN-009, A NEOANTIGEN VACCINE IN COMBINATION WITH PD-1 CHECK-POINT INHIBITORS (CPI) IN ADVANCED SOLID TUMORS
    Gillison, Maura
    Cohen, Roger
    Twardowski, Przemyslaw
    Sukari, Ammar
    Johnson, Melissa
    Lackner, Rudy
    Davis, Thomas
    DeCillis, Arthur
    Hernandez, Richard
    Price, Jessica
    Mancini, Kevin
    Shainheit, Mara
    Flechtner, Jessica
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A237 - A237
  • [39] Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
    Niu, Jiaxin
    Kaufman, Howard L.
    Kichenadasse, Ganessan
    Haydon, Andrew Mark
    Barve, Minal A.
    Ganju, Vinod
    Buchbinder, Elizabeth Iannotti
    Spira, Alexander I.
    Pang, Weijia
    Fu, Wenmin
    Zhao, Min
    Kirkwood, John M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Gemcitabine plus folfox 4 (GOLF) followed by subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) in colon carcinoma patients in second/third line of treatment. An update from the multicenter GOLFIG-1 phase II trial
    Correale, P.
    Remondo, C.
    Intrivici, C.
    Montagnani, F.
    Marsili, S.
    La Placa, M.
    Pascucci, A.
    Sciandivasci, A.
    Paolelli, L.
    Rotundo, M. Saveria
    Tagliaferri, P.
    Tassone, P.
    Venuta, S.
    Francini, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII148 - VII148
1234